A technology to ensure optimum cell performance for regenerative medicine

Lead Participant: PLASTICELL LIMITED

Abstract

The central issue of regenerative medicine is the capacity to reproducibly control the differentiation of a high proportion of stem cells. Because this is inherently influenced by many biological, chemical and physical cues, a very large number of experimental tests are required in each instance to determine the optimum outcome. By adding the power of advanced imaging and robotic microwell-based engineering to an already powerful combinatorial technique the proposed programme will create an internationally leading general technology for quickly and efficiently examining large numbers of linked variables. In this way it will create foundations for a powerful commercial activity applicable across the whole of the new industry.

Lead Participant

Project Cost

Grant Offer

PLASTICELL LIMITED £745,918 £ 405,724
 

Participant

THE HEALTH PROTECTION AGENCY (HPA NIBSC) £646,169 £ 318,690
UNIVERSITY COLLEGE LONDON £363,490 £ 363,490

People

ORCID iD

Publications

10 25 50